SCHEMBL9890714

SCHEMBL9890714

CNC(=O)Cc1ccccc1-c1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.49
SLC6A4 P31645 1/20 0.49
SLC6A3 Q01959 1/20 0.49
SUCNR1 Q9BXA5 3/20 0.46
PTGDR2 Q9Y5Y4 1/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
ADAMTS4 O75173 1/20 0.45
ADAMTS5 Q9UNA0 1/20 0.45
GCG P01275 1/20 0.44
CHRM1 P11229 1/20 0.44
CHRM3 P20309 1/20 0.44
POLB P06746 1/20 0.43
FFAR4 Q5NUL3 2/20 0.43
FFAR1 O14842 1/20 0.43
PTGS2 P35354 1/20 0.41
HTR7 P34969 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2397419 0.87 KMT2A (0.51) KMT2ACHRM1CHRM3FFAR4FFAR1
SCHEMBL2393550 0.84 SLC6A3 (0.48) SLC6A3MEN1KMT2AFFAR4FFAR1
SCHEMBL2391383 0.84 SLC6A4 (0.49) SLC6A4SLC6A3PTGDR2MEN1KMT2A
SCHEMBL9890716 0.84 CHRM1 (0.62) SUCNR1CHRM1CHRM3HTR7
SCHEMBL9890728 0.82 FFAR1 (0.46) SUCNR1PTGDR2ADAMTS4ADAMTS5CHRM1
SCHEMBL2393525 0.82 PTGDR2 (0.47) PTGDR2MEN1KMT2ACHRM1CHRM3
SCHEMBL9890718 0.81 KMT2A (0.49) CYP2C19MEN1KMT2A
SCHEMBL2395131 0.81 KCNJ5 (0.49) SLC6A4SLC6A3FFAR4FFAR1
SCHEMBL9890779 0.81 ALDH1A1 (0.44) CYP2C19SLC6A4SLC6A3PTGDR2MEN1
SCHEMBL3540535 0.80 SUCNR1 (0.56) CYP2C19SLC6A4SLC6A3SUCNR1PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CYP2C19 240/4885SLC6A4 932/4885SLC6A3 724/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CYP2C19 240/4885SLC6A4 932/4885SLC6A3 724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.